Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess whether the progression-free survival time under 5-FU/FA plus irinotecan plus cetuximab is longer than that under 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer.
Critère d'inclusion
- first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer